Mr. Matt Handel United States

ExpressCells is genetic-engineering company that creates custom and catalog knock-in cell lines for biological research. Our approach uses CRISPR plus our patent-pending plasmid system that creates cell lines up to 75% faster than older technologies and allows multiple knock-ins. Our living cells replicate diseases or have proteins glow in multiple colors, speeding drug development. We are generating revenue through e-commerce, online promotion, and sales representatives.

Website:
xpresscells.com
Company Size (Fulltime employees)
Year of foundation
2018
Please specify your partnering goal
Identify companies that can commercialize our cell lines in China and other Asian markets
Headquartner in China
Assets Information 1
Customer Knock-In Cell Lines
Assets Information 2
Catalog Cell Lines
Assets Information 3
Knock-in Stem Cells
Biotech/Pharma Asset Stage
Your Research Tool and Service name
Knock-in Cell Lines
Service Description
We create custom knock-in cell lines in as few as 30 days. Using our patent-pending FAST-HDR plasmid system, we can knock 1-3 genes into precise locations in cell lines. These knock-ins can be reporters, overexpression models, or have point mutations inserted.
Target client type
Research scientists in pharmaceuticals and biotech who conduct experiments on cell lines
Slides Deck
(pdf, 1.48MB)
ExpressCells
LinkedIn logo CEO 
Functionality

Dr. Lee Henderson United States

Gene Therapy company delivering Intrabodies with AAV delivery targeting misfolded proteins in neurodegenerative diseases. INT41 for Huntington’s Disease is our flagship product with successful results in cell based and animal models for Huntington's disease with additional indications. INT41 has Orphan Designation from the FDA.

Our platform selects Intrabodies that target novel intracellular mutations or stabilize refolding and can be applied to multiple therapeutic areas. 

Website:
Www.vybion.com
Company Size (Fulltime employees)
Year of foundation
2008
Please specify your partnering goal
Codevelopment with licensing or M&A option
Headquartner in China
Biotech/Pharma Category
Assets Information 1
INT41|Gene Therapy Intrabody|Huntington’s, spinocerebellar ataxia, spinomuscular atrophy|US, China, Europe, India, Australia, Canada
Biotech/Pharma Asset Stage
Slides Deck
(pdf, 422.47KB)
Vybion
CEO 
Functionality

Yan Henry United States

US dollar fund,focusing on medical device and Medtech area.
Partnering Objectives
Headquartner in China
Device of tomorrow capital llc
Managing partner 

Mr. Yao Ho United States

Healthcare investment firm with 1.3 billion AUM
Year of foundation
2015
Partnering Objectives
Headquartner in China
LYFE Capital
Sr. Director of BD 
Functionality

Laura Hong United States

Biologics Therapeutic development focUnited Statesed on oncology and IO. Looking for potential partnership opportunities for license in/out. www. KlUnited Statespharma.com
Partnering Objectives
Headquartner in China
Biotech/Pharma Category
KlUnited States Pharma
President 

Dr. Charles Hsu United States

Seed and startup-scale investor focused on healthcare. Also provides cross-border partnering services.
Crosswave Management
Managing Partner 
Functionality

Dr. Na Hu United States

Pharmaceutical
Website:
N/a
Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
N/a
Headquartner in China
Bms
Senior Manager 

Mr. Shunfu Hu United States

Biostage is a biotechnology company developing bioengineered organ implants to treat congenital defects, cancers and other life-threatening conditions of the esophagus, bronchus and trachea.

The company’s novel Cellframe™ technology is engineered to stimulate the body’s signaling pathways and natural healing process to regenerate and restore organ function. Our Cellframe technology is based on over 20 years of scientific progress in the fields of tissue engineering, cell biology and material science. Cellframe technology combines the best attributes of a synthetic scaffold with tissue engineering and cell biology to create what may be a revolutionary method of addressing organ damage.

Biostage has been developing its new generation of organ implants as a platform capable of being used in the esophagus and main airways (trachea and bronchi). The current platform, based on our Cellframe technology, represents a complete re-engineering of our earlier organ scaffold and cell technology to better stimulate the regenerative properties of each of these organs. Biostage’s Cellframe technology platform is used to create organ specific Cellspan implants. Recent large animal data showed promising results as our Cellframe technology applied to the esophagus achieved the regeneration of esophageal tissue.
Website:
www.biostage.com
Company Size (Fulltime employees)
Please specify your partnering goal
Fund raising, invest,
Headquartner in China
Biotech/Pharma Category
Biostage, Inc.
VP of Business Development and Operations 
Functionality

Dr. Helen Hua United States

A CAP, CLIA And AABB certified clinical lab specialized in genetic and molecular diagnosis
Website:
1800dnagenes.com
Company Size (Fulltime employees)
Year of foundation
1958
Please specify your partnering goal
Similar field
Headquartner in China
Biotech/Pharma Category
Medtech Category
Medical/Legal Genetics inc
MD, MS, MT(ASCP) 
Functionality

Zhenna Huang United States

MNC pharmaceuticals company
Website:
Amgen.com
Partnering Objectives
Headquartner in China
AMGEN
Research manager